Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report' returned 140 results - Page 1 of 8  FEATURED RESULTS Drug Delivery in Cancer - Technologies, Markets and Companies Cancer Diagnostic Testing World Markets Antibody Drug Target Atlas in Oncology MicroRNA Profiling in Cancer: A Bioinformatics Perspective Outcome Prediction in Cancer   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Lung Cancer Therapeutics Market Outlook and Pipeline Analysis   Arrowhead Publishers, Nov 2009 .6 Research and Development (R&D) Trends 1.7 Pipeline Analysis 2 LUNG CANCER: DISEASE BACKGROUND 2.1 An Introduction to Lung Cancer 2.2 An Overview of Non Small Cell Lung Cancer (NSCLC) 2.2.1 Squamous Cell Carcinoma 2 Drug Delivery in Cancer - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 639 -4: Drug delivery for hepatocellular carcinoma Table 5-5: Gene therapy for malignant melanoma Table 5-6: Targeted treatment of non-small cell lung cancer Table 5-7: Clinical trials of gene therapy Lung Cancer Therapeutics - Global Strategic Business Report   Global Industry Analysts, Inc., July 2009, Pages: 842 This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report   Life Science Analytics, March 2009, Pages: 831 cancer or small cell lung cancer drug pipeline. This report provides insight into the pipeline status of non-small-cell lung cancer or lung cancer or small cell lung cancer drugs by company and by stage Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning   Bioseeker, Aug 2009, Pages: 751 Breakdown of the Lung Cancer (general) Pipeline Figure 10: Breakdown of the Non-Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure Lung Cancer and Non-Small Cell Lung Cancer Therapy Area Pipeline Report   Life Science Analytics, March 2011, Pages: 1729 Lung Cancer and Non-Small Cell Lung Cancer Therapy Area Pipeline Report contains detailed information on the lung cancer and non-small cell lung cancer drug pipeline. This report provides insight Cancer Biologics Pipeline: Antibodies, Peptides, and Proteins - A Competitive Review   Decision Resources, Inc., April 2011, Pages: 29 and Challenges -- Melanoma -- Non-Small-Cell Lung Cancer -- Breast Cancer 2010 and Market Outlook - Market Statistics - Market Drivers and Constraints About the Author - Abbott Laboratories - Amgen Pipeline Insight: Lung Cancers Overview - Intensive R&D activity but little improvement in patient outcomes   Datamonitor, Dec 2010, Pages: 167 products Highlights - There are 134 drugs in development for non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Molecular targeted therapies constitute the bulk (73%) of the pipeline Spanish Lung Cancer Group - Developmental Therapeutics Review - Q4 2010   Global Markets Direct, Dec 2010, Pages: 28 ’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Spanish Lung Cancer Group in its therapy areas of focus. - Identify new drug targets Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth   GBI Research, Sep 2010, Pages: 78 in the cancer types such as cervical cancer, NSCLC (non-small cell lung cancer), breast cancer, gastric cancer, head cancer, colon cancer and many others that will be launched in the next few years Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline   Bioseeker, Oct 2010, Pages: 659 for the Treatment of non-Hodgkin's Lymphoma Table 90: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer Table 91: The Competition through Close Mechanistic A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market   Bioseeker, Nov 2010, Pages: 777 Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer Table 91: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs Table 92 Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development   GBI Research, Dec 2011, Pages: 215 . The report provides an in-depth analysis of major oncology indications, which includes breast cancer, colorectal cancer, Non-Hodgkin’s Lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017   GlobalData, Dec 2010, Pages: 64 Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Non-Small Cell Lung Cancer Cancer Therapies - Global Strategic Business Report   Global Industry Analysts, Inc., Oct 2011, Pages: 897 Stage as of 2010 (includes corresponding Graph/Chart) 53 Lung Cancer 54 Select FDA-Approved Non-Small Cell Lung Cancer Drugs 54 Table 15: Lung Cancer Drug Pipeline: Number of Drugs by Development Non-Small Cell Lung Cancer - Pipeline Review, H2 2011   Global Markets Direct, Sep 2011, Pages: 605 Cancer therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage Lung Cancer Drug Pipeline Update 2011   Bioseeker, Feb 2011 Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies   GBI Research, Feb 2011, Pages: 209 Cancer 6.6.3 Non-Small Cell Lung Cancer (NSLC) 6.6.4 Breast Cancer 6.6.5 Colon Cancer 6.6.6 Melanoma 6.6.7 Ovarian Cancer 6.6.8 Prostate Cancer 7 Drug Discovery and Preclinical Molecules by Therapy Non-Small Cell Lung Cancer - Pipeline Review, Q1 2011   Global Markets Direct, Feb 2011, Pages: 538 Cancer therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018   GlobalData, Jan 2012, Pages: 147 and the US, Oncovex for melanoma Stimuvax (BLP25 liposome vaccine) for unresectable stage III NSCLC (non-small cell lung cancer). Due to the launch of first-in-class vaccines during the forecast Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network